SEC Form 4 · accession 0001144204-16-130730
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jed Latkin
Officer — Interim COO
Period of report
Oct 14, 2016
Accepted (ET)
Nov 1, 2016 · 10:29 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.00 | Oct 14, 2016 | A | 20,000 | A | — | Oct 14, 2026 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Option vests to the extent of 10,000 shares each month over a period of two months commencing November 20, 2016.